IDH1 and central nervous system cancer: Further, amongst IDH1/2-wild-type tumors, where MGMT-methylation status is instrumental for therapeutic selection, almost a fifth of high-grade gliomas and more than 3-quarters of low-grade gliomas were not assessed for MGMT status.